Details of Disease

General Information of Disease (ID: DISO5KRQ)

• Disease Name: Progressive supranuclear palsy
• Synonyms: familial progressive supranuclear palsy (type); supranuclear palsy, progressive; progressive supranuclear ophthalmoplegia; PSP syndrome; Steele-Richardson-Olszewski disease; Steele-Richardson-Olszewski syndrome
• Disease Class: 8A00: Parkinsonism
• Definition: A rare late-onset neurodegenerative disease characterized by supranuclear gaze palsy, postural instability, progressive rigidity, and mild dementia.
• Disease Hierarchy:
  DIS6SVEE: Syndromic disease
  DIS8ANWQ: Supranuclear oculomotor palsy
  DISPN7D2: Inherited neurodegenerative disorder
  DISOJJ2D: Movement disorder
  DISO5KRQ: Progressive supranuclear palsy
• ICD Code:
  ICD-11: ICD-11: 8A00.10
  ICD-10: ICD-10: G23.1
  Expand ICD-11: '8A00.10
  Expand ICD-10: 'G23.1
• Disease Identifiers:
  MONDO ID: MONDO_0019037
  MESH ID: D013494
  UMLS CUI: C0038868
  MedGen ID: 21026
  Orphanet ID: 683
  SNOMED CT ID: 192976002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABBV-8E12	DMHLIQU	Phase 2	NA	[1]
BIIB092	DM263RP	Phase 2	NA	[2]
TPI 287	DM3I5NU	Phase 2	NA	[3]
TPI-287	DMC5TV6	Phase 2	Small molecular drug	[4]
BMS-986168	DMOSS5Z	Phase 1	NA	[3]
MK 8719	DMFLP21	Phase 1	NA	[5]
MK-8719	DMETIBD	Phase 1	Small molecular drug	[6]

This Disease is Treated as An Indication in 1 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID29334795-Compound-21	DMTOA1Q	Patented	Small molecular drug	[7]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 21 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
SLCO1A2	TTUGD21	Limited	Genetic Variation	[8]
SP1	TTZEP6S	Limited	Genetic Variation	[8]
CIT	TT3BKTU	moderate	Genetic Variation	[9]
GABRG2	TT06RH5	moderate	Biomarker	[10]
MOBP	TTYUK4F	moderate	Genetic Variation	[8]
RUNX2	TTD6SZ8	moderate	Genetic Variation	[8]
C9orf72	TTA4SHR	Strong	Genetic Variation	[11]
DNAJB1	TTPXAWS	Strong	Biomarker	[12]
DUSP10	TTF3RJ0	Strong	Genetic Variation	[13]
EIF2AK3	TT79U1M	Strong	Biomarker	[14]
GBA	TT1B5PU	Strong	Genetic Variation	[15]
LAMC2	TTNS7H3	Strong	Genetic Variation	[16]
MAOB	TTGP7BY	Strong	Biomarker	[17]
MSMB	TTYH1ZK	Strong	Biomarker	[18]
MUSK	TT6SA0X	Strong	Biomarker	[19]
PPME1	TTXQ54R	Strong	Biomarker	[20]
SLC6A3	TTVBI8W	Strong	Biomarker	[21]
SPOCK1	TTF23RE	Strong	Biomarker	[22]
TARDBP	TT9RZ03	Strong	Biomarker	[11]
TGM1	TT7A949	Strong	Biomarker	[23]
GRN	TT0LWE3	Definitive	Biomarker	[24]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC25A38	DTV8SWX	Strong	Biomarker	[25]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
GLDC	DEIN8FB	moderate	Biomarker	[26]

This Disease Is Related to 45 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
BNIP1	OT7USYCY	Limited	Genetic Variation	[11]
OPN1MW	OTPJ7LX4	Limited	Biomarker	[27]
PLCG2	OTGVC9MY	Limited	Genetic Variation	[28]
SETX	OTG3JNOQ	Limited	Genetic Variation	[11]
TRIM11	OTMD6IM2	Limited	Genetic Variation	[29]
ASAP1	OT4DLRYY	moderate	Genetic Variation	[8]
NSF	OTKRJ2ZT	moderate	Genetic Variation	[26]
PIK3C2G	OTW3LY1C	moderate	Genetic Variation	[29]
STH	OTK8ULTH	moderate	Altered Expression	[30]
STX6	OTC5F5M6	moderate	Genetic Variation	[8]
AP2A2	OTD1UGUN	Strong	Biomarker	[31]
ARL17B	OTXZD3DG	Strong	Biomarker	[32]
BPIFA2	OTLFSDZD	Strong	Biomarker	[18]
BSN	OTZ72VIB	Strong	Genetic Variation	[33]
CD8B	OTMZ1T7J	Strong	Genetic Variation	[34]
CSDC2	OTQH3VSR	Strong	Biomarker	[35]
CTNNBL1	OT6KLHPA	Strong	Biomarker	[36]
DCTN1	OT5B51FJ	Strong	Genetic Variation	[37]
DLX1	OT7BH057	Strong	Altered Expression	[38]
FLAD1	OTY8R02L	Strong	Biomarker	[19]
IGLON5	OTB94PY2	Strong	Biomarker	[39]
IRF4	OT1DHQ1P	Strong	Genetic Variation	[34]
LCMT1	OTRJQ16X	Strong	Genetic Variation	[20]
LMOD1	OTZ2MEMG	Strong	Biomarker	[40]
MCIDAS	OTK1JVAH	Strong	Biomarker	[41]
MINK1	OTKB0RA8	Strong	Genetic Variation	[42]
NEFL	OTQESJV4	Strong	Biomarker	[43]
NPC1	OTRIPICX	Strong	Biomarker	[44]
NPC2	OTE9UEJC	Strong	Genetic Variation	[45]
PICALM	OTQVRPMQ	Strong	Genetic Variation	[46]
PSPC1	OTYS6WQ8	Strong	Genetic Variation	[47]
PSPH	OTV1PVAX	Strong	Biomarker	[18]
PSPN	OT54LLZJ	Strong	Biomarker	[18]
RAB35	OTRH1E2T	Strong	Altered Expression	[48]
RAPSN	OTGMSWDQ	Strong	Biomarker	[19]
REG1A	OTMHUH1D	Strong	Biomarker	[18]
RIDA	OTW4098I	Strong	Biomarker	[18]
SCRN1	OTELM5C2	Strong	Biomarker	[49]
SNCAIP	OTH8VNOK	Strong	Genetic Variation	[50]
SPECC1	OTPEML48	Strong	Genetic Variation	[51]
SRSF2	OTVDHO6U	Strong	Biomarker	[52]
STXBP3	OTTTYMAQ	Strong	Biomarker	[18]
TCOF1	OT4BOYTM	Strong	Biomarker	[53]
TMEM106B	OTUWA6NW	Strong	Genetic Variation	[54]
TRA2B	OTZYQW52	Strong	Biomarker	[52]

References

• [1] ClinicalTrials.gov (NCT02985879) A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT03068468) Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT). U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT02133846) Safety Study of TPI-287 to Treat CBS and PSP (TPI-287-4RT). U.S. National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. J Med Chem. 2019 Nov 27;62(22):10062-10097.
• [7] Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
• [8] Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases.Mol Neurodegener. 2018 Aug 8;13(1):41. doi: 10.1186/s13024-018-0270-8.
• [9] Classification of degenerative parkinsonism subtypes by support-vector-machine analysis and striatal (123)I-FP-CIT indices.J Neurol. 2019 Jul;266(7):1771-1781. doi: 10.1007/s00415-019-09330-z. Epub 2019 Apr 29.
• [10] Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP.Transl Psychiatry. 2018 Dec 13;8(1):265. doi: 10.1038/s41398-018-0319-z.
• [11] Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum.JAMA Neurol. 2018 Jul 1;75(7):860-875. doi: 10.1001/jamaneurol.2018.0372.
• [12] Failure in heat-shock protein expression in response to UBB+1 protein in progressive supranuclear palsy in humans.Neurosci Lett. 2004 Apr 8;359(1-2):94-8. doi: 10.1016/j.neulet.2003.12.127.
• [13] Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci.Mol Neurodegener. 2018 Jul 9;13(1):37. doi: 10.1186/s13024-018-0267-3.
• [14] The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease.Acta Neuropathol Commun. 2013 Jul 6;1:31. doi: 10.1186/2051-5960-1-31.
• [15] GBA-associated parkinsonism and dementia: beyond -synucleinopathies?.Eur J Neurol. 2016 Mar;23(3):520-6. doi: 10.1111/ene.12894. Epub 2015 Nov 9.
• [16] Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum.Neurology. 2018 Apr 3;90(14):e1231-e1239. doi: 10.1212/WNL.0000000000005261. Epub 2018 Mar 7.
• [17] Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy.Neuroimage Clin. 2019;24:102091. doi: 10.1016/j.nicl.2019.102091. Epub 2019 Nov 13.
• [18] Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.Mov Disord. 2019 Aug;34(8):1144-1153. doi: 10.1002/mds.27619. Epub 2019 Feb 6.
• [19] Pena-Shokeir phenotype (fetal akinesia deformation sequence) revisited.Birth Defects Res A Clin Mol Teratol. 2009 Aug;85(8):677-94. doi: 10.1002/bdra.20611.
• [20] Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.J Neuropathol Exp Neurol. 2018 Feb 1;77(2):139-148. doi: 10.1093/jnen/nlx110.
• [21] Presynaptic Striatal Dopaminergic Function in Atypical Parkinsonism: A Metaanalysis of Imaging Studies.J Nucl Med. 2019 Dec;60(12):1757-1763. doi: 10.2967/jnumed.119.227140. Epub 2019 Apr 12.
• [22] Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes.J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):768-773. doi: 10.1136/jnnp-2018-320151. Epub 2019 Mar 13.
• [23] Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.J Neuropathol Exp Neurol. 2003 Feb;62(2):173-84. doi: 10.1093/jnen/62.2.173.
• [24] Parkinsonism, movement disorders and genetics in frontotemporal dementia.Nat Rev Neurol. 2016 Mar;12(3):175-85. doi: 10.1038/nrneurol.2016.14. Epub 2016 Feb 19.
• [25] Appoptosin Mediates Lesions Induced by Oxidative Stress Through the JNK-FoxO1 Pathway.Front Aging Neurosci. 2019 Sep 4;11:243. doi: 10.3389/fnagi.2019.00243. eCollection 2019.
• [26] Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia.Acta Neuropathol. 2017 May;133(5):825-837. doi: 10.1007/s00401-017-1693-y. Epub 2017 Mar 7.
• [27] Non-Alzheimer's disease dementias: anatomic, clinical, and molecular correlates.Can J Psychiatry. 2004 Mar;49(3):164-71. doi: 10.1177/070674370404900303.
• [28] ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans.Mol Neurodegener. 2018 Oct 11;13(1):53. doi: 10.1186/s13024-018-0289-x.
• [29] Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype.Ann Neurol. 2018 Oct;84(4):485-496. doi: 10.1002/ana.25308. Epub 2018 Sep 15.
• [30] Tau and saitohin gene expression pattern in progressive supranuclear palsy.Brain Res. 2007 May 11;1145:168-76. doi: 10.1016/j.brainres.2007.01.098. Epub 2007 Feb 1.
• [31] Alzheimer Disease Pathology-Associated Polymorphism in a Complex Variable Number of Tandem Repeat Region Within the MUC6 Gene, Near the AP2A2 Gene.J Neuropathol Exp Neurol. 2020 Jan 1;79(1):3-21. doi: 10.1093/jnen/nlz116.
• [32] Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci.Acta Neuropathol. 2016 Aug;132(2):197-211. doi: 10.1007/s00401-016-1576-7. Epub 2016 Apr 26.
• [33] Mutations in bassoon in individuals with familial and sporadic progressive supranuclear palsy-like syndrome.Sci Rep. 2018 Jan 16;8(1):819. doi: 10.1038/s41598-018-19198-0.
• [34] Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.Nat Genet. 2011 Jun 19;43(7):699-705. doi: 10.1038/ng.859.
• [35] Prognostic importance of apathy in syndromes associated with frontotemporal lobar degeneration.Neurology. 2019 Apr 2;92(14):e1547-e1557. doi: 10.1212/WNL.0000000000007249. Epub 2019 Mar 6.
• [36] NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.PLoS One. 2019 Mar 13;14(3):e0213666. doi: 10.1371/journal.pone.0213666. eCollection 2019.
• [37] DCTN1 F52L mutation case of Perry syndrome with progressive supranuclear palsy-like tauopathy.Parkinsonism Relat Disord. 2018 Jun;51:105-110. doi: 10.1016/j.parkreldis.2018.02.038. Epub 2018 Feb 23.
• [38] Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1.Nat Commun. 2018 Jul 26;9(1):2929. doi: 10.1038/s41467-018-05325-y.
• [39] IgLON5-Associated Encephalitis With Atypical Brain Magnetic Resonance Imaging and Cerebrospinal Fluid Changes.Front Neurol. 2018 May 17;9:329. doi: 10.3389/fneur.2018.00329. eCollection 2018.
• [40] The neuropathology of a chromosome 17-linked autosomal dominant parkinsonism and dementia ("pallido-ponto-nigral degeneration").J Neuropathol Exp Neurol. 1998 Jun;57(6):588-601. doi: 10.1097/00005072-199806000-00006.
• [41] Mild Cognitive Impairment and Progression to Dementia in Progressive Supranuclear Palsy.Neurodegener Dis. 2017;17(6):286-291. doi: 10.1159/000479110. Epub 2017 Sep 8.
• [42] Mutational study of the nuclear factor kappa B inducing kinase gene in patients with progressive supranuclear palsy.Neurosci Lett. 2003 Apr 10;340(2):158-60. doi: 10.1016/s0304-3940(03)00105-8.
• [43] Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.JAMA Neurol. 2019 Mar 1;76(3):318-325. doi: 10.1001/jamaneurol.2018.3746.
• [44] Role of Niemann-Pick Type C Disease Mutations in Dementia.J Alzheimers Dis. 2017;55(3):1249-1259. doi: 10.3233/JAD-160214.
• [45] Niemann-Pick C disease gene mutations and age-related neurodegenerative disorders.PLoS One. 2013 Dec 30;8(12):e82879. doi: 10.1371/journal.pone.0082879. eCollection 2013.
• [46] Screening of Early and Late Onset Alzheimer's Disease Genetic Risk Factors in a Cohort of Dementia Patients from Liguria, Italy.Curr Alzheimer Res. 2015;12(8):802-12. doi: 10.2174/1567205012666150710114751.
• [47] Similarities between familial and sporadic autopsy-proven progressive supranuclear palsy.Neurology. 2013 May 28;80(22):2076-8. doi: 10.1212/WNL.0b013e318294b2eb. Epub 2013 May 1.
• [48] Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease.J Clin Neurol. 2019 Oct;15(4):488-495. doi: 10.3988/jcn.2019.15.4.488.
• [49] Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.Acta Neuropathol Commun. 2019 Dec 3;7(1):195. doi: 10.1186/s40478-019-0848-6.
• [50] Multiple system atrophy/progressive supranuclear palsy: alpha-Synuclein, synphilin, tau, and APOE.Neurology. 2000 Dec 26;55(12):1918-20. doi: 10.1212/wnl.55.12.1918.
• [51] Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4.Neuropathol Appl Neurobiol. 2003 Oct;29(5):503-10. doi: 10.1046/j.1365-2990.2003.00453.x.
• [52] Mitochondrial complex 1 inhibition increases 4-repeat isoform tau by SRSF2 upregulation.PLoS One. 2014 Nov 17;9(11):e113070. doi: 10.1371/journal.pone.0113070. eCollection 2014.
• [53] Transcranial sonography in atypical parkinsonism: How reliable is it in real clinical practice? A multicentre comprehensive study.Parkinsonism Relat Disord. 2019 Nov;68:40-45. doi: 10.1016/j.parkreldis.2019.09.032. Epub 2019 Oct 1.
• [54] TMEM106B haplotypes have distinct gene expression patterns in aged brain.Mol Neurodegener. 2018 Jul 3;13(1):35. doi: 10.1186/s13024-018-0268-2.